ActHIB <unk> -vaccine) Effective vaccines for<unk>  Type B have been available since the early 1990s, and are recommended for children under age 5 and asplenic patients. The World Health Organization recommends a pentavalent vaccine, combining vaccines against diphtheria, tetanus, pertussis, hepatitis B and<unk> . There is not yet sufficient evidence on how effective this pentavalent vaccine is in relation to the individual vaccines.<unk>  vaccines cost about seven times the total cost of vaccines against measles, polio, tuberculosis, diphtheria, tetanus, and pertussis. Consequently, whereas 92% of the populations of developed countries were vaccinated against<unk>  as of 2003, vaccination coverage was 42% for developing countries, and only 8% for least-developed countries. The<unk>  vaccines do not provide cross-protection to any other<unk>  serotypes like<unk> a,<unk> c,<unk> d,<unk> e or<unk> f. An oral vaccination has been developed for non-typeable<unk>  (NTHi) for patients with chronic bronchitis but it has not shown to be effective in reducing the number and severity of COPD exacerbations. However, there is no effective vaccine for the other types of capsulated<unk>  or<unk>  nontypeable.
Haemophilus influenzae
Bordetella pertussis
Streptococcus bovis
Neisseria meningitidis
Bacillus anthracis
Rhodococcus equi
Bordetella bronchiseptica
Streptococcus pyogenes